CN Patent

CN109069589B — 用于心血管病况的司美鲁肽

Assigned to Novo Nordisk AS · Expires 2022-09-06 · 4y expired

What this patent protects

本发明涉及用于医药的GLP‑1受体激动剂司美鲁肽。

USPTO Abstract

本发明涉及用于医药的GLP‑1受体激动剂司美鲁肽。

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

Patent Metadata

Patent number: CN109069589B
Jurisdiction: CN
Classification: —
Expires: 2022-09-06
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.